outline
DESCRIPTION
The regulation of Nicotine-Containing Products (NCPs) UK National Smoking Cessation Conference 28 June 2013 Jeremy Mean. Outline. MHRA and the regulation of Nicotine-Containing Products (NCPs) Main features of medicines regulation European proposals for regulating NCPs UK Government action. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/1.jpg)
The regulation of Nicotine-Containing Products (NCPs)
UK National Smoking Cessation Conference
28 June 2013
Jeremy Mean
![Page 2: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/2.jpg)
2
Outline
• MHRA and the regulation of Nicotine-Containing Products (NCPs)
• Main features of medicines regulation
• European proposals for regulating NCPs
• UK Government action
![Page 3: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/3.jpg)
3
Role of the MHRA
• The Medicines and Healthcare products Regulatory Agency (MHRA) is the Government Agency responsible for ensuring medicines and devices work and are acceptably safe – a statutory role
• The Agency is part of the Department of Health and supports the Government’s wider public health policies
• This includes reducing the impact of smoking on public health and how NCPs are regulated
![Page 4: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/4.jpg)
4
All of these products contain nicotine
![Page 5: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/5.jpg)
5
All of these products contain nicotine
NCPsregulated by MHRA These products are
NOT regulated by MHRA
![Page 6: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/6.jpg)
6
Public consultation
• Growing concerns about safety and quality of products on the UK market
• Growing acceptance of harm reduction approach to smoking
“..to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them”
![Page 7: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/7.jpg)
7
Outcome of consultation
Against MHRA regulation For MHRA regulationSome importers Medical professional
bodies,Users of NCPs NHS, pharmaceutical
industry tobacco industry trading
standards some importers
![Page 8: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/8.jpg)
8
Working with stakeholders
Researchers-UKCTCSProf Hajek
Pharma ECITA
NICE, DH, BIS,
No. 10
Public Health Sector
MHRA
![Page 9: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/9.jpg)
9
Research
• Investigation of the levels of nicotine
• The nature, quality and safety of unlicensed NCPs
• The actual use of unlicensed NCPs in the marketplace
• The efficacy of unlicensed NCPs in smoking cessation
• The potential impact of bringing these products into medicines regulation on public health outcomes
![Page 10: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/10.jpg)
10
Summary of main findings
• Nicotine levels vary from the labelled content and from batch to batch
• Variable content and nicotine delivery
• Unlicensed NCPs fail to meet standards of safety, quality and efficacy
• Most NCP used to support stop smoking or harm reduction
• Limited evidence of effectiveness
• Current regulation does not serve public health
![Page 11: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/11.jpg)
11
Main features of medicines regulation
• Proportionate licensing regime
• Labelling and product information
• Sale and Supply
• Advertising controls
• Safety monitoring
• Risk management tools
![Page 12: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/12.jpg)
12
European proposals on NCPs
• Part of wider Tobacco Products Directive
• Nicotine threshold approach
• Medicines licence required for some products
• Warnings for others
![Page 13: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/13.jpg)
13
UK Government action
• Regulation of NCPs as medicines serves the public health
• MHRA stands ready to license NCPs now
• UK Government will press for EU law to create a Europe wide legal position on NCPs as medicines
• This will mean all NCPs will require a medicines licence
![Page 14: Outline](https://reader035.vdocuments.us/reader035/viewer/2022070411/568148c6550346895db5e392/html5/thumbnails/14.jpg)
The regulation of Nicotine-Containing Products (NCPs)
UK National Smoking Cessation Conference
28 June 2013
Jeremy Mean